Metabolomic profiling of *Sansevieria trifasciata* hort ex. Prain leaves and roots by HPLC-PAD-ESI/MS and its hepatoprotective effect via activation of the NRF2/ARE signaling pathway in an experimentally induced liver fibrosis rat model

M. A. Raslan<sup>a\*</sup>, R. F. Abdel-Rahman<sup>b</sup>, H. M. Fayed <sup>b</sup>, H. A. Ogaly<sup>c,d</sup> and R. F. Taher<sup>e</sup>

<sup>a</sup> Pharmacognosy Department, National Research Centre, Dokki, 12622 Giza, Egypt.

<sup>b</sup> Pharmacology Department, National Research Centre, Giza 12622, Egypt.

<sup>c</sup> Department of Chemistry, College of Science, King Khalid University, Abha 61421, Saudi Arabia

<sup>d</sup> Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt

<sup>e</sup> Natural Compounds Chemistry Department, National Research Centre, Dokki, Giza, Egypt.

\* Corresponding author. E-mail address: monaazzam78@gmail.com

**Supplementary Figures** 



**Figure 1:** Peak 1: Tetrahydroxy spirosta-diene-triacetyldeoxyhexoside dipentoside hexoside [M-H]<sup>-</sup>: 1157.

**Figure 2:** Peak 2: Tetrahydroxy spirosta-diene- triacetyl deoxyhexoside dipentoside deoxyhexose [M-H]<sup>-</sup>: 1141.



**Figure 3:** Peak 3: Raffinose [M-H]<sup>-</sup>: 503.



**Figure 4:** Peak 4: Isovitexin hexoside [M-H]<sup>-</sup>: 593.



**Figure 5:** Peak 5: Tetrahydroxyspirosta-dien acetyldeoxyhexoside pentoside deoxyhexoside [M-H]<sup>-</sup>: 925.



**Figure 6:** Peak 6: Aucubin [M-H]<sup>-</sup>: 345.



**Figure 7:** Peak 7: Pentahydroxy spirostane trihexoside [M-H]<sup>-</sup>: 965.





**Figure 8:** Peak 8: Dihydroxypregna-5,16-dien-20-one deoxyhexoside pentoside hexoside [M-H]<sup>-</sup>: 769.



**Figure 9:** Peak 9: feruloylquinic acid [M-H]<sup>-</sup>: 367.



Figure 10: Peak 10: Neoruscogenin deoxyhexoside dipentoside [M-H]<sup>-</sup>: 837.



**Figure 11:** Peak 11: Isovitexin deoxyhexoside [M-H]<sup>-</sup>: 577.



Figure 12: Peak 12: caffeoyl–feruloyltartaric acid [M-H]<sup>-</sup>: 487.





Figure 14: Peak 14: Picroside II [M-H]<sup>-</sup>: 511.



Figure 15: Peak 15: Lucidenic acid A [M-H]<sup>-</sup>: 457.





**Figure 16:** Peak 16: Hydroxyhispidin dihexoside [M-H]<sup>-</sup>: 585.

**Figure 17:** Peak 17: Isovitexin [M-H]<sup>-</sup>: 431.





280.8333

300

m/z

319,7000

30-

20-

10

0

143.5000

150

207.3667

200

224.1333

250

443.0666

372.9667

400

350

452.0666

462.73

450

Figure 18: Peak 18: Scoparin (Chrysoeriol 8-C-glucoside) [M-H]<sup>-</sup>: 461.



**Figure 19:** Peak 19: Pechueloic acid [M-H]<sup>-</sup>: 247.

**Figure 20:** Peak 20: 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-[(E)-2-phenylethenyl] benzoic acid [M-H]<sup>-</sup>: 391.





Figure 21: Peak 21: Coumaroylquinic acid [M-H]<sup>-</sup>: 337.



Figure 22: Peak 22: Coumaric acid hexoside [M-H]<sup>-</sup>: 325.



Figure 23: Peak 23: 4'-O-(2'-Feruloylglucuronyl)-(1-2)-glucuronyl Apigenin [M-H]<sup>-</sup>: 797.



Figure 24: Peak 24: Trifasciatine A [M-H]<sup>-</sup>: 327.











Figure 27: Peak 27: Kaempferol hexoside [M-H]<sup>-</sup>: 447.







Figure 29: Peak 29: Trihydroxyfurost-en deoxyhexoside pentoside dihexoside [M-H]<sup>-</sup>: 1063.



Figure 30: Peak 30: Catechin hexoside [M-H]<sup>-</sup>: 451.



**Figure 31:** Peak 31: Isorhamnetin dihexoside [M-H]<sup>-</sup>: 639.

**Figure 32:** Peak 32: 6-((6-ethyl-4-hydroxy-5-methyl-2-oxo-2H-pyran-3-yl) methyl)-5,7-dihydroxy-2-phenylchroman-4-one [M-H]<sup>-</sup>: 421.



**Figure 33:** Peak 33: Dihydroxypregna-5,16-dien-20-one deoxyhexoside dipentoside [M-H]<sup>-</sup>: 739.





Figure 34: Peak 34: Trihydroxyspirosta-diene-diacetyl deoxyhexoside dipentoside [M-H]<sup>-</sup>: 937.







Figure 36: Peak 36: Methylophiopogonanone A [M-H]<sup>-</sup>: 341.



**Figure 37:** Peak 37: methyl 4-[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl) propan-2-yl] oxy-3-methoxybenzoate [M-H]<sup>-</sup>: 377.



**Figure 38:** Peak 38: Pinocembrine [M-H]<sup>-</sup>: 255.



**Figure 39:** Peak 39: Tetrahydroxy spirosta-diene- diacetyl deoxyhexoside dipentoside deoxyhexose [M-H]<sup>-</sup>: 1099.



Figure 40: Peak 40: Kaempferol hexoside deoxyhexoside [M-H]<sup>-</sup>: 593.

Figure 41: Peak 41: Martynoside [M-H]<sup>-</sup>: 651.





**Figure 42:** Peak 42: Tetrahydroxy spirosta-diene-diacetyldeoxyhexoside dipentoside [M-H]<sup>-</sup>: 953.



**Figure 43:** Peak 43: Eriodictyol dihexoside [M-H]<sup>-</sup>: 611.



Figure 44: Peak 44: Trihydroxy spirosta-diene- deoxyhexoside dipentoside [M-H]<sup>-</sup>: 853.



**Figure 45:** Peak 45: Trihydroxyspirostane hexoside pentoside [M-H]<sup>-</sup>: 741.



**Figure 46:** Peak 46: Monogalloyl-hexoside [M-H]<sup>-</sup>: 331.



**Figure 47:** Peak 47: Hydroxydihydrocaffeoylquinic acid [M-H]<sup>-</sup>: 371.



**Figure 48:** Peak 48: Isokaemferide (5,7,4<sup>-</sup>-trihydroxy-3-methoxyflavone) [M-H]<sup>-</sup>: 299.



**Figure 49:** Peak 49: Dihydroxy methoxyfurost--diene deoxyhexoside trihexoside [M-H]<sup>-</sup>: 1075.



Figure 50: Peak 50: Hydroxyspirost-en deoxyhexoside pentoside hexoside [M-H]<sup>-</sup>: 869.



Figure 51: Peak 51: Trihydroxy spirosta-diene acetyl deoxyhexoside dipentoside [M-H]<sup>-</sup>: 895.



**Figure 52:** Peak 52: Dihydroxypregna-5,16-dien-20-one deoxyhexoside pentoside acetyl hexoside [M-H]<sup>-</sup>: 811.



Figure 53: Peak 53: Dimethoxy hydroxyflavone [M-H]<sup>-</sup>: 297.



**Figure 54:** Peak 54: Hexahydroxy methoxyfurostane dihexoside [M-H]<sup>-</sup>: 835.



**Figure 55:** Peak 55: Trihydroxychalcone [M-H]<sup>-</sup>: 255.

Figure 56: Peak 56: Protocatechuic acid hexoside [M-H]<sup>-</sup>: 315.



Protocatechuic acid hexoside

[M-H]<sup>-</sup>: 315.0699





**Figure 57:** Peak 57: Chlorogenic acid [M-H]<sup>-</sup>: 353.



Figure 58: Peak 58: Hesperetin [M-H]<sup>-</sup>: 301.



Figure 59: Peak 59: Tetrahydroxy spirosta-diene acetyl deoxyhexoside dipentoside [M-H]<sup>-</sup>: 911.



**Figure 60:** Peak 60: Dihydroxy-dimethoxyflavanone [M-H]<sup>-</sup>: 315.



**Figure 61:** Peak 61: Acacetin [M-H]<sup>-</sup>: 283.



Figure 62: Peak 62: Caffeoyl–feruloylquinic acid [M-H]<sup>-</sup>: 529.



Figure 63: Peak 63: Kaempferol [M-H]<sup>-</sup>: 285.



Figure 64: Peak 64: Caftaric acid [M-H]<sup>-</sup>: 311.

Figure 65: Peak 65: Ruscogenin [M-H]<sup>-</sup>: 429.



Figure 66: Peak 66: Neoruscogenin [M-H]<sup>-</sup>: 427.

